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Breast cancer is the leading cause of death in women worldwide.The search for novel compounds with antitumor activity, with less
adverse effects and higher efficacy, and the development of methods to evaluate their toxicity is an area of intense research. In this
study we implemented the preparation and culture of breast tumor explants, which were obtained from precision-cut breast tumor
slices. In order to validate themodel we are proposing to screen antineoplastic effect of natural compounds, we selected caffeic acid,
ursolic acid, and rosmarinic acid. Using the Krumdieck tissue slicer, precision-cut tissue slices were prepared from breast cancer
samples; from these slices, 4mm explants were obtained and incubated with the selected compounds. Viability was assessed by
Alamar Blue assay, LDH release, and histopathological criteria. Results showed that the viability of the explants cultured in the
presence of paclitaxel (positive control) decreased significantly (𝑃 < 0.05); however, tumor samples responded differently to each
compound. When the explants were coincubated with paclitaxel and compounds, a synergic effect was observed.This study shows
that ex vivo culture of breast cancer explants offers a suitable alternative model for evaluating natural or synthetic compounds with
antitumor properties within the complex microenvironment of the tumor.
1. Introduction
Cancer is the leading cause of mortality worldwide, with 8.2
million deaths and 14.1 million new cases recorded during
2012 alone. According to the World Health Organization, the
number of deaths will continue to rise across the globe, with
the alarming prediction of 19.3 million new cases by 2025.
Breast cancer is the most frequent cancer found in women; it
possesses the most elevated morbidity and mortality. In 2012,
approximately 1.7 million women were diagnosed with breast
cancer in the world, and 522,000 died as a direct result of this
disease [1].
Conventional cancer therapies include surgery, radiation,
and chemotherapy. Although the latter is widely used, inmost
cases it produces undesirable side effects. Chemoresistance
and/or recurrence of cancer after chemotherapy are frequent
events seen with treatment of this disease [2]. Thus, different
research groups are now focused on finding novel drugs or
anticancer compounds [3, 4] while others are developing
methodologies for the evaluation of these drugs [5–7].
One of the current approaches for investigating novel
antineoplastic or chemopreventive compounds is based on
natural products research. This is because some of these
compounds inhibit cell proliferation and promote apoptosis
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Table 1: Bioactive compounds in commonly used herbs and spices.
Caffeic acid Rosmarinic acid Ursolic acid
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Coffee, parsley Rosemary Basil
Cardamom, rosemary Marjoram Marjoram
Cumin, sage Oregano Sage
Fennel, tarragon Basil Thyme
Nutmeg, thyme Sage
Oregano Thyme
in various types of tumor cells including breast cancer cells.
Furthermore, it is well known that approximately 60% of the
drugs administered in cancer treatment were isolated from
natural products [8–10].
For the purpose of this study, we selected three nat-
urally occurring compounds which possess antitumor and
chemopreventive activities, namely, caffeic acid (CA), ursolic
acid (UA), and rosmarinic acid (RA). These bioactive com-
pounds are present in fruits, vegetables, medicinal plants,
and culinary species. Table 1 shows their chemical structures
and some examples of culinary herbs and spices where they
are abundantly found [11–13]. CA is known to inhibit DNA
methylation in human breast cancer cells and it has been
suggested that it may reduce the risk of acquiring breast
cancer [14]; however, epidemiological studies have been
inconsistent and no established association between coffee
intake and breast cancer development has been discovered
[15]. We have previously reported that CA obtained from
Hedeoma drummondii extracts possesses antiproliferative
effect against MCF-7 and HeLa cells [16]. UA is known to
inhibit proliferation of MCF-7 cells [17, 18], induce apoptosis,
and inhibit oxygen consumption in various tumor cell lines
[19, 20]. It suppresses the migration and invasion of MDA-
MB-231 cells [21] and exerts antitumor effects on multidrug-
resistant cancer cells [22]. RA has antioxidant, antitumor,
antimutagenic, and chemopreventive activities [12, 23–25].
The effect of RA on cell proliferation and apoptosis induction
has been determined in MCF-7, MDA-MB-361, MDA-MB-
453, and HeLa cells [26, 27]; RA induces apoptosis and
inhibits metastasis of MDA-MB-231BO cells. Hence, RA
is also considered a good candidate for new therapeutic
approaches in the treatment of breast cancer [28].
On the other hand, the antitumor activity and mecha-
nisms involved in the inhibition of carcinogenesis by novel
compounds with antineoplastic potential must be evaluated
and validated using models that extrapolate their effects in
humans. The results obtained from cells cultured in vitro
and from experiments conducted on animals do not reflect
what happens in humans, especially with regard to the full
physiology, metabolism, pharmacokinetics, and other fac-
tors of high complexity. Therefore, it is important to use
experimental models for easy and proper observation of
the effects of bioactive compounds in tumor samples where
tumor microenvironment is preserved. Conde et al. suggest
that to study behavior of tumors it is necessary to maintain or
reconstitute a similar environment of the tumor in situ [29].
From the experimental point of view, a way to preserve tissue
architecture with little or no manipulation is through the
organotypic culture of intact and fresh tumor tissues. Tissue
slices, one of the methods recently used, is an intermediate
system between in vivo and in vitro models, which offers a
new perspective to the results obtained with cell lines.
Tissue slices contain virtually all the cells from the tissue
under study. They retain histological and three-dimensional
structure (3D), with inter- and extracellular interactions, cell
matrix components, and,most interestingly,metabolic capac-
ity. Hence, cultured tissue slices are considered a suitable tool
for the study of multicellular processes [30].
Precision-cut tissue slices have mainly been used to study
metabolism and toxicity of xenobiotics [31, 32], biotransfor-
mation of drugs, gene expression studies, and morphological
analysis, among other studies [33, 34]. Our group has recently
described their application as an infection model for the
parasitic protozoa Entamoeba histolytica [35, 36]. Other than
normal tissue slices, tumor slices are 3D cultures in which it
is possible to evaluate ex vivo therapeutic efficacy of oncolytic
vectors [37–41] and drugs such as meloxicam and Taxol [42–
44] or study the interactions between stromal components
and epithelial cells with the extracellular environment, as well
as the response to cytokines and drugs [45].The taxoid pacli-
taxel (abbreviated TX in this work), known by its original
brand name, Taxol, represents the most important first-line
antineoplastic drug for treatment of various types of cancer,
including breast cancer, ovarian cancer, non-small cell lung
cancer, andAIDS relatedKaposi’s sarcoma, among others. TX
was purified and identified as the active constituent from the
bark of the Pacific yew, Taxus brevifolia, in 1971 [46, 47]. Its
mechanism of action relies on the promotion of microtubule
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Table 2: Clinical and histopathological data of the subjects.
Patient Age Clinical stage Histologic type Tumorsize
Estrogen
receptor (ER)
Progesterone
receptor (PR) Her2 status
Molecular
classification
A 50 yr T2N1M0 (grading: IIB) Ductal infiltrating 3 cm (−) (−) (+) Her2+
B 59 yr T3N0M0 (grading: IIB) Ductal infiltrating 5 cm (+) (+) (+) Luminal B
C 41 yr T2N1M0 (grading: IIB) Ductal infiltrating 4 cm (+) (+) (−) Luminal A
assembly and inhibition of microtubule disassembly; cells
exposed to paclitaxel cannot form a mitotic spindle; this
interferes with cell division and induces cell death [48].
Using ex vivo organotypic cultures of breast cancer
explants treated with CA, UA, RA, and TX, we found that this
model is an alternative system for studying anticancer activity
or synergistic potential assessing natural products. Cultured
explants retain their typical morphology and viability for
at least 3 days. With this method, a sufficient number of
slices and explants can be obtained from minimal amounts
of tissue, enabling the study of several compounds within a
single tumor specimen.
2. Materials and Methods
2.1. Chemicals. Caffeic acid, ursolic acid, rosmarinic acid,
paclitaxel, and insulin-transferrin-selenium were purchased
from Sigma-Aldrich (St. Louis, MO, USA). DMEM/F12
medium, fetal bovine serum, gentamicin, penicillin-strep-
tomycin, and Alamar Blue were obtained from Invitrogen
(Grand Island, NY, USA). The antibody against Ki 67 was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). The reagents for general use were purchased from
Sigma-Aldrich (St. Louis, MO, USA).
2.2. Tumor Samples. Infiltrating ductal adenocarcinoma
specimens were collected from 11 patients during surgery at
the Hospital of Gynecology and Obstetrics (UMAE # 23)
from the Mexican Institute of Social Security (IMSS). The
pathologist dissected the specimen immediately after surgery
to confirm its tumorous nature and to avoid contamination.
Informed consent was obtained from all patients. Tissues
were collected in cold serum-free DMEM/F12 medium
(Invitrogen, Grand Island, NY, USA) and transported at 4∘C
to the organotypic culture laboratory for immediate process-
ing. Approval was obtained from the Institutional Review
Board (Mexican Institute of Social Security) before initiation
of studies on human tissue.The clinical and histopathological
data of these patients are described in Table 2.
2.3. Preparation of Slices and Explants from Breast Tumor.
From representative tumor samples, cylindrical tissue cores
of 10mm diameter were obtained; from these, tissue slices of
250–300𝜇m thickness were prepared using the Krumdieck
tissue slicer (Alabama Research & Development, Munford,
AL, USA), with constant flow of Krebs Henseleit bicarbonate
buffer (KB) at 4∘Cwhichwas gassed with carbogen.The slices
were collected in KB buffer at 4∘C. To optimize the tumor
sample and homogenize the size of tissues, small tumor
explants, 4mm in diameter and 250–300𝜇m in thickness,
were prepared using a biopsy punch from the first-obtained
slices. Tumor explants were placed in six-well microplates
containing DMEM/F12 culture medium supplemented with
10% fetal bovine serum, 5 𝜇g/mL bovine insulin, 100 𝜇g/mL
gentamicin, insulin-transferrin-selenium, and 25mM glu-
cose (DMEM/F12 supplementedmedium). Plates were prein-
cubated for 1 h at 37∘C, 5% CO
2
/95% air, and agitation at
25 rpm. The interval between resection of the tumor and the
incubation of the explants was no more than 2 h. The entire
process was performed under aseptic conditions.
2.4. Viability of Tumor Explants. In order to confirm that the
tumor sampleswere still viable during the entire experiments,
the viability of the tumor explants was determined at different
times before testing the antineoplastic effect of CA, UA, and
RA. To test this, explants with 4mm diameter/250–300 𝜇m
thickness were placed in 24-well microplates containing 1mL
of DMEM/F12 supplemented medium and incubated for 4
days at 37∘C, 5% CO
2
/95% air, and constant agitation of
25 rpm.Viability was determined every 24 h in a group of four
explants. Protocols for metabolic viability (AB), cytotoxicity
(LDH release), cellular proliferation (Ki 67 expression),
and morphological integrity (histopathological analysis) are
described in the corresponding section. The culture medium
was changed every 24 h through 96 h, and each time viability,
proliferation, and morphology were assessed.
2.5. Treatment of Tumor Explants with TX and Bioactive
Compounds. After 1 h of preincubation, the tumor explants
were transferred to 24-well microplates containing 1mL of
DMEM/F12 supplemented medium. Afterwards, the follow-
ing compounds were added: 20𝜇g/mL TX (positive control),
11–33 𝜇g/mL CA, 20–60𝜇g/mL for RA and UA, and combi-
nations of these compounds with TX. These concentrations
were selected on the basis of IC
50
values reported in cell
lines [16, 20, 49]. Control group (100% viability) consisted of
untreated explants, which were incubated only with culture
medium. Afterwards, the microplate with the explants and
their corresponding treatments were incubated for 48 h at
37∘C, 5% CO
2
/95% air, and constant agitation at 25 rpm.
2.6. Alamar Blue Viability Assay. The effect of treatment with
CA, UA, and RA on the viability of the tumor explants
was assessed by the Alamar Blue assay. Alamar Blue (AB)
is a blue nonfluorescent dye reduced to a pink-colored,
highly fluorescent resorufin by metabolically active cells. It
is known that viable cells reduce the microenvironment to
a pink color, while dead or inactive cells do not change
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the original blue color of resazurin, the active ingredient of
AB. After 48 h of incubation with compounds, as well as
with cell culture medium and TX (controls), the explants
were incubated for additional 4 h with 10% Alamar Blue
in 500𝜇L DMEM/F12 supplemented medium at 37∘C in
the conditions described earlier. Afterwards, 100 𝜇L was
collected from each sample and transferred to a 96-well
microplate. Fluorescence values were read using a multin-
ode microplate reader (Synergy BioTek HT) at 530 nm
excitation/590 nm emission wavelengths. The percentage
of viability relative to control was calculated using the
free software AbD Serotec fluorometric calculator for AB
assays (http://www.abdserotec.com/colorimetric-calculator-
fluorometric-alamarblue.html).
2.7. Lactate Dehydrogenase Assessment. Another way to
assess the viability of the explants treatedwith the compounds
and that of the untreated controls was by assessment of the
leakage of the enzyme lactate dehydrogenase (LDH) into
the supernatant of the culture medium [50]. The assay is
based on the release of the cytosolic enzyme LDH into the
media by cells with damaged plasma membranes [51]. The
cytotoxicity induced by CA, UA, and RA on the tumor
explants can be quantitatively determined by measuring the
activity of this enzyme. The total amount of released enzyme
was determined using an Architect C400 clinical chemical
analyzer (Abbott).
2.8. Histopathological Analysis. After each experimental time
point, the explants were fixed in 10% neutral formalin and
then embedded in paraffin using the conventional histo-
logical technique. Tissue sections of 4𝜇m were prepared
on a microtome and mounted on glass slides. Afterwards,
the slides were deparaffinized and stained with hematoxylin
and eosin (H&E). Then permanent sections were prepared
with coverslips and synthetic resin. The stained preparations
were observed by a pathologist using a Zeiss Axiostar
Plus Brightfield microscope. Morphological parameters ana-
lyzed in treated and control explants included necrosis,
viable/damaged tumor cells, and inflammation. Represen-
tative photographs of all treatments were obtained with a
5.0MP Moticam camera.
2.9. Immunohistochemistry for Ki 67 Expression. Analysis of
Ki 67 expression was performed on paraffin sections using
the Dako LSAB System-HRP methodology to assess the
rate of cell proliferation from treated and untreated tumor
explants. The procedure was performed according to the
recommendations of themanufacturer.The expression of this
marker is nuclear, and the proliferation index was defined
as follows: low: expression in ≤10% of cells; intermediate:
expression in 10–20% of cells; and high: expression in ≥20%
of cells [52].
2.10. Statistical Analysis. Statistical analysis was performed
with SPSS version 22.0 software. Quantitative data were
expressed as mean and standard deviation. Differences in
continuous variables with normal distribution were analyzed
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Figure 1: Viability of cultures breast cancer explants. To determine
the optimal time for performing the experiments with bioactive
compounds, explants were cultivated in DMEM/F12 supplemented
medium for 24, 48, 72, and 96 h. The viability was assessed by the
Alamar Blue assay. Values reflect means ± SD. Asterisks (∗) indicate
significant statistical differences (𝑃 < 0.05).
with Student’s t-test or theMann-Whitney𝑈 test for nonnor-
mal distributions.
3. Results
3.1. Characteristics of Patient Samples Used for the Preparation
and Culture of Breast Cancer Tissue Explants. Eleven samples
of human breast cancer with histopathological diagnosis of
infiltrating ductal adenocarcinoma with nonspecific pattern
were collected fresh from the operating room.Three samples
were used to standardize and optimize the preparation of
precision-cut breast tumor slices, and, from these, explants
of a defined size and thickness (4mm in diameter and
250–300𝜇m thick) were obtained for ex vivo culture under
controlled conditions. Three more samples were used to
standardize the concentrations to test each of the bioactive
compounds and TX. Three other samples were included in
three independent assays to assess the effect of CA, UA, RA,
and TX on the viability of tumor tissue explants. The last two
samples were discarded due to abundant necrosis, as well as
elevated adipose and fibrous tissues, which prevented proper
processing.
3.2. Viability of Tumor Explants
3.2.1. Metabolic Activity: Alamar Blue Assay. Tumor explants
cultured for 24 and 48 h remained viable throughout the
incubation period, with mean viability of 99% compared to
basal value (100%). At 72 h, a slight decrease was observed
in viability (84.7% ± 10.2), whereas, at 96 h, the percentage
decreased to 55.1% ± 17.9 (𝑃 < 0.05). These results showed
the metabolism of explants of breast tumors, and hence,
their viability remained intact during at least the first 48 h
of culture. With these results, we decided that 48 h was the
optimal time to perform cytotoxicity assays with the bioactive
compounds (Figure 1).
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Figure 2: Morphological integrity of tumor tissue explants cultured ex vivo. Histopathological findings of tumor tissue at zero time (basal)
and cultivated during different times inDMEM/F12 supplementedmedium show that neoplastic tissue remains viable. It is possible to observe
cells in active mitosis (M), desmoplastic reaction (DR) adjacent to the tumor cells, and presence of inflammatory cells (arrow). Desmoplasia
or desmoplastic reaction is usually only associated with malignant neoplasms, which can evoke a fibrosis response by invading healthy tissue.
All these characteristics are typical of tumor tissue. (a) 0 h, (b) 24 h, (c) 48 h, (d) 72 h, and (e) 96 h in culture, respectively. H&E staining (40x).
3.2.2. Morphological Integrity: Histopathological Analysis.
After 96 h in culture, it was found that the typical histology of
the tumor tissue was preserved in breast tumor explants. As
shown in Figure 2, in the explants cultured for 24, 48, 72, and
96 h, neoplastic cells retained their characteristicmorphology
and mitotic activity. It was possible to identify microcal-
cifications, fibrous connective tissue, desmoplastic stromal
reaction, inflammatory cells, and adipose tissue; furthermore,
mitotic cells were observed at all-time points. These results
(as shown in Figure 3) confirm that breast cancer explants
remained viable and actively proliferating for up to 96 h.
3.2.3. Proliferative Activity: Immunohistochemical Expression
of Ki 67. Compared to normal breast and tumor tissues
(negative and positive controls, resp.), the proliferation index
of the cultivated explants was greater than 50% during all the
incubation times (24–72 h). This result corresponds to a high
proliferation index according to the criteria defined in Mate-
rials and Methods and suggests that the tissue remains viable
and actively proliferating during ex vivo culture conditions
(Figure 3).
3.2.4. Effects of Bioactive Compounds and TX on Breast Tumor
Explants. In order to ascertain that the breast tumor explants
responded to the ex vivo treatment with CA, UA, and RA,
we decided to first evaluate the metabolic activity of these
explants after 48 h of incubation with varying doses of TX (5,
10, 15, and 20𝜇g/mL). As expected, a dose-response curve of
cytotoxicity, directly proportional to the concentration of TX,
was observed. Since 20𝜇g/mL of TX reduced tumor viability
to less than 50% (𝑃 < 0.05), we selected this concentration
for assays in which TX was a reference for antineoplastic
activity (Figure 4). In the case of the effect of the bioactive
compounds on the viability of breast tumor explants, the
initial concentrations tested for CA, UA, and RA were 11–33,
20–60, and 20–60 𝜇g/mL, respectively. These concentrations
were not cytotoxic since the explants remained viable and
also conserved their intact histological structure (data not
shown). Because of this, it was necessary to increase the
experimental concentrations of CA andUA to 100 𝜇g/mL and
of RA to 120 𝜇g/mL.
When the histological structure of uncultured tumor
explants was compared with explants cultivated for 48 h
without any treatment, poorly differentiated neoplastic with
nonspecific pattern neoplastic cells, which retained their
viability, were observed. However, when the explants were
cultured in the presence of only TX and with combinations
of TX plus bioactive compounds, scattered necrotic areas
as well as a remarkable reduction (more than 40%) in the
population of neoplastic cells were also observed (Figure 5).
These results suggest a potential antineoplastic effect of the
bioactive compounds, reinforced when they are combined
with TX. Additionally, by analyzing the metabolic activity
of the explants incubated with these new concentrations, it
was observed, as expected, that individual samples from each
patient responded differently to the tested compounds. CA
was the most effective in patient A, reducing tumor viability
to 67.2%, while the combination of TX + CA decreased
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Figure 3: Nuclear expression of the cell proliferation marker Ki 67 in cultures of breast cancer explants. Representative images showing that
over 40% of the neoplastic cells express Ki 67 at all-time points. The proliferation index is considered “high” when >20% of the cells are
positive for this marker. (a) Normal breast tissue (negative control); (b) breast tumor (positive control); (c), (d), and (e) breast tumor explants
cultured for 24, 48, and 72 h, respectively. Immunohistochemical staining (10x).
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Figure 4: Effect of paclitaxel on the viability of tumor explants.
Breast tumor explants were cultured during 48 h in the presence
of different concentrations of paclitaxel. The viability was assessed
at the indicated times using the Alamar Blue assay. Values reflect
means ± SD. Asterisks (∗) indicate significant statistical differences
(𝑃 < 0.05).
viability to 17.1%. Likewise, CAwas themost active compound
against the tumor of patient B, in which viability was reduced
by 32.5; also, combination with TX had an important effect
on viability, with a reduction of 20.2%. In contrast, none
of the compounds had a cytotoxic effect against the patient
C sample; however, a marked reduction in viability was
observed when individual compounds combined with TX
were tested. Interestingly, all of the compounds exerted a
synergistic effect, enhancing the tissue toxicity of TX in all
three tumor samples (Figure 6).
The cytotoxicity of TX alone and combinations with
bioactive compounds was assessed via the release of the
cytosolic enzyme LDH into the supernatants from the culture
media in which tumor explants were cultivated. As shown
by the data, the combination of TX + CA induced 1.42- and
1.80-fold increase of LDH release in the tumor explants from
patients A and B, respectively, compared to untreated control.
For patient C, the combination of TX with RA induced a
2.34-fold increase (Figure 7). These values were statistically
significant (𝑃 < 0.05).
4. Discussion
The aim of this study was to demonstrate the use of ex vivo
organotypic culture of human breast tumor explants as an
alternative model system for evaluating natural compounds
with antineoplastic potential. The most important character-
istic of these explants is that they are obtained fromprecision-
cut breast tissue slices which possess a defined size and
thickness.
This is an interesting model which allows the study of
different aspects of cancer. It has all the advantages of normal
BioMed Research International 7
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Figure 5: Effect of the bioactive compounds and their combinationwith paclitaxel on cultures of breast cancer explants. Explants from control
at zero h (a) and control without any treatment cultured for 48 h (b) show poorly differentiated invasive neoplasm and no evidence of tumor
necrosis areas. In contrast, in explants incubated with TX (c) and their combinations with CA (d), RA (e), and UA (f), an evident pathological
response was observed, which is mainly reflected as a notable diminution of the neoplastic cells (40–80%) which can be appreciated as
extensive areas of necrosis induced by treatments (dotted lines) H&E staining (10x).
tissues slices and also contributes to the significant decrease
in the number of animals used in experimentation [30,
35]. Also, it enables the optimization of the amount of
available tissue and favors the realization of a large number of
assays that capture many aspects of tumor heterogeneity and
complexity [53]. One of the difficulties we faced during the
preparation of breast tumor sliceswas the viscosity or the very
soft consistency of some tumors; thus, based on this fact, 2 of
the 11 samples were discarded. This disadvantage correlated
with those reported by other investigators [54, 55].
To be certain that this system is reliable and adequate
to assess the effect of these bioactive compounds, the most
critical step was to maintain the viability of the explants
during ex vivo culture conditions and during subsequent
treatment with these compounds. To monitor viability, we
used the AB assay because it is a simple and affordable
method that allows assessing cell viability by adding AB
reagent directly to the culturemedium.The active compound
of AB is resazurin, which is reduced to resorufin through
mitochondrial metabolism in living cells. Moreover the AB
assay does not require additional steps as do other viability
tests, in which it is necessary to lyse or damage cell mem-
branes in order to release the reducedmetabolite [56, 57].This
assay gives reliable measurements of the number of metabol-
ically active cells and is one of the most commonly used
methods for assessing cell proliferation. Other advantages
include its homogeneous nature, the stability of generated
signal, high sensitivity, compatibility with absorbance or
fluorescence instruments anddifferent biologicalmodels, and
also safety for the user and the environment [58, 59]. The
results from histopathological and AB analysis demonstrate
that bothmetabolic activity andmorphological integrity were
conserved for at least 72 h (Figures 1 and 2).
On the other hand, immunohistochemical analysis of Ki
67 showed that cellular proliferation remained stable over
the experimental period. Ki 67 is a proliferation marker
strongly associated with cells undergoing mitosis in the
cellular cycle [60]. Proliferation index in cancer cells from
cultivated explants was >40% in all-time points, which is
considered “high” according to accepted criteria (Figure 3)
[52] and is similar to the reports from other authors, who
conducted tests of selective toxicity in breast cancer tissue and
were able to maintain viability and proliferation for 24 h [61]
and 96 h [44, 62] or up to 7 days [55].
In order to validate the usefulness of the model, we incu-
bated the breast tumor explants with different concentrations
of TX, a well-known antineoplastic drug. As was expected,
a dose-response curve was observed (Figure 4). With results
from three different tumor samples, we used 20𝜇g/mL
as a positive control in the following studies. Afterwards,
three independent experiments were carried out to test the
effect of CA, UA, and RA, which are naturally occurring
products whose anticancer and chemopreventive properties
have been reported previously [10, 12, 14, 21, 22, 63, 64].
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Figure 6: Effect of different treatments on the viability of breast cancer explants. Tumor explants were incubated with the bioactive
compounds for 48 h and then cell viability was determined using the Alamar Blue assay. Control explants did not receive any treatment.
Concentrations of compounds were 100𝜇g/mL CA and UA, 120 𝜇g/mL RA, and 20 𝜇g/mL TX. The same concentrations were used in
the combinations. Results were compared to the untreated control. Values reflect means ± SD. Asterisks (∗) indicate significant statistical
differences (𝑃 < 0.05) compared to control. Pound key (#) indicates significant statistical differences (𝑃 < 0.05) compared to paclitaxel.
The concentrations used first were selected on the basis of
IC
50
values reported in cell lines [16, 20, 49]; however, we did
not observe a cytotoxic effect on the tumor tissue explants.
This can be attributed to the differences between in vitro cell
cultures and tissue explants, because in tissue explants there
is more than one cell lineage interacting with each other and
with extracellular matrix components. It is well known that
the extracellular matrix and the tumor microenvironment
protect neoplastic cells from cytotoxic agents [65]. When
we increased the concentrations of the bioactive compounds
to 100 𝜇g/mL for CA and UA and 120 𝜇g/mL for RA, we
found that CA had the greatest effect, decreasing in tumor
viability (Figure 6). The concentration used for CA, as well
as the results observed, was similar to those described by
Chang et al., who reported that CA induced apoptosis and
decreased viability in gastric cancer cells [66].
With regard to the synergistic effect between the bioactive
compounds and TX, there are several reports using cell
lines which combine antineoplastic agents with extracts from
phenolic compounds, such as UA and RA, which enhance
treatments effectiveness. These results suggest a great poten-
tial for the use of natural compounds, when added to TX or
another antineoplastic agent, in order to reduce the dosage,
and the side effects associated with chemotherapy, without
sacrificing therapeutic results [67–70].
In addition to the aforementioned, performing such
studies in organotypic ex vivo models, such as the one
used in this work, which more closely resemble an in vivo
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Figure 7: Effect of the combinations of paclitaxel with bioactive compounds on LDH release. Four tumor explants per treatment were
incubated with combinations of TX and compounds for 48 h and then LDH activity was quantified bymeasuring the units of enzyme released
into the supernatants from the culturemedium.Control explants received no treatment. Concentrations in the combinationswere 20 𝜇g/mL +
100𝜇g/mL (TX + CA and TX + UA) and 20𝜇g/mL + 120𝜇g/mL (TX + RA). Results of LDH release are expressed as fold of change relative
to control. Values represent means ± SD. Asterisks (∗) indicate significant statistical differences (𝑃 < 0.05).
scenario, might be more useful for extrapolating results
in humans. An important factor to be considered is the
administration time of the bioactive compound to the tissue,
which can be done before, during, or after incubation with
the antineoplastic agent. In our case, we coincubated tumor
explants in the presence of compounds plus TX based on
the experimental points we previously defined; however, new
assays can be designed by pretreating or posttreating tissues
with different compounds and antineoplastic agents. When
combinations of CA, UA, or RA plus TX were studied,
CA acted synergistically with this antineoplastic drug since
viability was lower than with TX alone (Figure 6). This
result is different from those reported by Lin et al., who
found that CA at 100–150 𝜇M induced a slight increase in
the proliferation of A549 and H1299 lung cancer cells and
that pretreatment of cells with CA protects these cells from
growth inhibition when they are incubated with TX [71].This
discrepancy in the results can be attributed to the difference in
biological models (cell lines versus tumor explants), the pre-
treatment used, and also the fact that the CA concentrations
were different. Furthermore, RA induced more pronounced
membrane damage when coadministered with TX in the
sample from patient C (Figure 7). Although the synergism
between CA and TX was the strongest, a synergistic response
in reducing tumor viability for all compounds compared to
compounds alone was observed (Figure 6).
The relationship between viability and cytotoxicity data is
discrete since, although it is possible to observe that at lower
percentage of viability LDH release increases, the values of
LDH are relatively low considering that viability decreased
at an average of 18% in the synergies between TX + CA in
patients A and B and TX + RA in patient C; therefore one
would expect LDH levels to be more elevated. One possible
explanation for this fact is that inactivation of the enzyme
could have occurred in the culture medium, as has been
reported by Lash and Zalups, Kendig and Tarloff, Hohnholt
et al., and Tulpule et al. [72–75]. Another possibility is
that some natural compounds that have antioxidant effects
protect cells and prevent the release of LDH. For example,
da Silva Morrone et al. found that extracts of Passiflora
manicata leaves protect from damage induced by reactive
oxygen species, and the release of LDH was significantly
reduced in precision-cut rat liver slices [76]. On the other
hand, Liu et al. found that lipopolysaccharides obtained from
Lycium barbarum inhibited the elevation of liver enzymes,
among them, LDH in slices of liver exposed to carbon
tetrachloride [77]. We believe that these last two reports
may better explain our findings because these authors also
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used tissue slices, while, in the reports mentioned above,
cell cultures were used. On the other hand, as was described
in the introduction, the bioactive compounds we used have
antioxidant properties. These findings suggest that inacti-
vation or inhibition of LDH may be more common than
previously thought, and investigators should be aware of this
at the moment of selecting LDH release as an endpoint for
evaluating cytotoxicity.
Taken together, variability in the obtained results is
possibly due to the fact that each patient’s tumor behaves
differently to anticancer drugs, which in turn is due in part to
the extensive intratumoral heterogeneity present in each indi-
vidual tumor [43, 78].With regard to the last statement, since
the 1950s, differential responses to the same drugs in patients
with the same histological type of cancer have been reported,
including adverse side effects [79]. These differences have
been studied in the following years and today it is an accepted
fact that individual response to drugs (resistance or sensi-
tivity) depends, among other factors, on the mechanisms of
disease (pharmacodynamics), the handling of the drug by
patients (pharmacokinetics), the intratumoral heterogeneity,
and complex signaling pathways, many of which are still
unknown [78, 80, 81]. All these variations are reflected in
the intratumoral heterogeneity because of factors that cause
genomic instability [29, 78]. Intratumoral heterogeneity and
the tumor microenvironment are conserved in the ex vivo
model we are proposing, and it is possibly one of the reasons
why the response to bioactive compounds is different in
samples from patients, even when they had breast cancer
at the same clinical stage, the same histological type, but
different molecular classification.
5. Conclusions
In conclusion, our results show that organotypic cultures of
breast cancer explants offer an alternative model for the ex
vivo evaluation of novel compoundswith potential anticancer
properties, assessing the synergic effect with known anti-
cancer compounds. This model opens perspectives to study
biological effects of conventional and innovative treatment
strategies in breast cancer research and to analyze different
mechanisms of carcinogenesis in other human tumors.
Conflict of Interests
The authors declare that they have no conflict of interests.
Acknowledgments
This work was partially supported by a grant from the Fondo
de Investigacio´n en Salud (CIS/IMSS) FIS/IMSS/PROT/
G1145. Irma Edith Carranza-Torres received a Fellowship for
Ph.D. studies from CONACYT (no. 338954).
References
[1] J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN
2012 v1.0, Cancer Incidence and Mortality Worldwide in 2012:
IARC Cancer Base No.11, International Agency for Research on
Cancer, Lyon, France, 2013, http://globocan.iarc.fr.
[2] L. Vera-Ramirez, P. Sanchez-Rovira, C. L. Ramirez-Tortosa, J. L.
Quiles, M. Ramirez-Tortosa, and J. A. Lorente, “Transcriptional
shift identifies a set of genes driving breast cancer chemoresis-
tance,” PLoS ONE, vol. 8, no. 1, Article ID e53983, 2013.
[3] C. Morrissey, B. Gallis, J. W. Solazzi et al., “Effect of artemisinin
derivatives on apoptosis and cell cycle in prostate cancer cells,”
Anti-Cancer Drugs, vol. 21, no. 4, pp. 423–432, 2010.
[4] G.-J. Du, Q. Dai, S. Williams, C.-Z. Wang, and C.-S. Yuan,
“Synthesis of protopanaxadiol derivatives and evaluation of
their anticancer activities,” Anti-Cancer Drugs, vol. 22, no. 1, pp.
35–45, 2011.
[5] H. J. Kang, S. H. Lee, J. E. Price, and L. S. Kim, “Curcumin
suppresses the paclitaxel-induced nuclear factor-kappaB in
breast cancer cells and potentiates the growth inhibitory effect
of paclitaxel in a breast cancer nude mice model,” The Breast
Journal, vol. 15, no. 3, pp. 223–229, 2009.
[6] Y. Wang, L. Rouggly, M. You, and R. Lubet, “Animal models
of lung cancer: characterization and use for chemoprevention
research,” Progress in Molecular Biology and Translational Sci-
ence, vol. 105, pp. 211–226, 2012.
[7] X.-W. Yang, X.-L.Wang, L.-Q. Cao et al., “Green tea polyphenol
epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell
growth inhibition of hepatocellular carcinoma cells,” Hepatol-
ogy Research, vol. 42, no. 5, pp. 494–501, 2012.
[8] A. J. Alonso-Castro, M. L. Villarreal, L. A. Salazar-Olivo,
M. Gomez-Sanchez, F. Dominguez, and A. Garcia-Carranca,
“Mexican medicinal plants used for cancer treatment: pharma-
cological, phytochemical and ethnobotanical studies,” Journal
of Ethnopharmacology, vol. 133, no. 3, pp. 945–972, 2011.
[9] K.-K. Bai, F.-L. Chen, Z. Yu, Y.-Q. Zheng, Y.-N. Li, and Y.-
H. Guo, “Synthesis of [3𝛽-acetoxy-urs-12-en-28-oyl]-1-mono-
glyceride and investigation on its anti tumor effects against
BGC-823,” Bioorganic and Medicinal Chemistry, vol. 19, no. 13,
pp. 4043–4050, 2011.
[10] I. Berdowska, B. Zielin´ski, I. Fecka, J. Kulbacka, J. Saczko, and
A. Gamian, “Cytotoxic impact of phenolics from Lamiaceae
species on human breast cancer cells,” Food Chemistry, vol. 141,
no. 2, pp. 1313–1321, 2013.
[11] C. M. Kaefer and J. A. Milner, “The role of herbs and spices in
cancer prevention,”The Journal of Nutritional Biochemistry, vol.
19, no. 6, pp. 347–361, 2008.
[12] A. Link, F. Balaguer, and A. Goel, “Cancer chemoprevention by
dietary polyphenols: promising role for epigenetics,” Biochemi-
cal Pharmacology, vol. 80, no. 12, pp. 1771–1792, 2010.
[13] H.Wang, T. O. Khor, L. Shu et al., “Plants vs. cancer: a review on
natural phytochemicals in preventing and treating cancers and
their druggability,” Anti-Cancer Agents in Medicinal Chemistry,
vol. 12, no. 10, pp. 1281–1305, 2012.
[14] W. J. Lee and B. T. Zhu, “Inhibition of DNA methylation
by caffeic acid and chlorogenic acid, two common catechol-
containing coffee polyphenols,”Carcinogenesis, vol. 27, no. 2, pp.
269–277, 2006.
[15] G. L. Gierach, N. D. Freedman, A. Andaya et al., “Coffee intake
and breast cancer risk in the NIH-AARP diet and health study
cohort,” International Journal of Cancer, vol. 131, no. 2, pp. 452–
460, 2012.
[16] E. Viveros-Valdez, C. Rivas-Morales, A. Oranday-Ca´rdenas, J.
Castro-Garza, and P. Carranza-Rosales, “Antiproliferative effect
from the Mexican poleo (Hedeoma drummondii),” Journal of
Medicinal Food, vol. 13, no. 3, pp. 740–742, 2010.
BioMed Research International 11
[17] D. Es-Saady, A. Simon, C. Jayat-Vignoles, A. J. Chulia, and
C. Delage, “MCF-7 cell cycle arrested at G1 through ursolic
acid, and increased reduction of tetrazolium salts,” Anticancer
Research, vol. 16, no. 1, pp. 481–486, 1996.
[18] C. Mart´ın-Cordero, M. Reyes, M. J. Ayuso, and M. V. Toro,
“Cytotoxic triterpenoids fromErica andevalensis,”Zeitschrift fur
Naturforschung Section C: Journal of Biosciences, vol. 56, no. 1-2,
pp. 45–48, 2001.
[19] I. Lee, J. Lee, Y. H. Lee, and J. Leonard, “Ursolic acid-induced
changes in tumor growth, O
2
consumption, and tumor intersti-
tial fluid pressure,” Anticancer Research, vol. 21, no. 4, pp. 2827–
2833, 2001.
[20] E. Kassi, T. G. Sourlingas, M. Spiliotaki et al., “Ursolic acid
triggers apoptosis and Bcl-2 downregulation in MCF-7 breast
cancer cells,” Cancer Investigation, vol. 27, no. 7, pp. 723–733,
2009.
[21] C.-T. Yeh, C.-H. Wu, and G.-C. Yen, “Ursolic acid, a naturally
occurring triterpenoid, suppresses migration and invasion of
human breast cancer cells by modulating c-Jun N-terminal
kinase, Akt and mammalian target of rapamycin signaling,”
Molecular Nutrition & Food Researc, vol. 54, no. 9, pp. 1285–
1295, 2010.
[22] J.-Z. Shan, Y.-Y. Xuan, S.-Q. Ruan, and M. Sun, “Proliferation-
inhibiting and apoptosis-inducing effects of ursolic acid and
oleanolic acid on multi-drug resistance cancer cells in vitro,”
Chinese Journal of Integrative Medicine, vol. 17, no. 8, pp. 607–
611, 2011.
[23] M. A. Furtado, L. C. F. de Almeida, R. A. Furtado, W. R. Cunha,
andD.C. Tavares, “Antimutagenicity of rosmarinic acid in Swiss
mice evaluated by themicronucleus assay,”Mutation Research—
Genetic Toxicology and Environmental Mutagenesis, vol. 657, no.
2, pp. 150–154, 2008.
[24] M. Shekarchi, H. Hajimehdipoor, S. Saeidnia, A. R. Gohari, and
M. P.Hamedani, “Comparative study of rosmarinic acid content
in some plants of Labiatae family,” Pharmacognosy Magazine,
vol. 8, no. 29, pp. 37–41, 2012.
[25] K. Venkatachalam, S. Gunasekaran, V. A. S. Jesudoss, and
N. Namasivayam, “The effect of rosmarinic acid on 1,2-
dimethylhydrazine induced colon carcinogenesis,” Experimen-
tal and Toxicologic Pathology, vol. 65, no. 4, pp. 409–418, 2013.
[26] J. Paluszczak, V. Krajka-Kuz´niak, andW. Baer-Dubowska, “The
effect of dietary polyphenols on the epigenetic regulation of
gene expression inMCF7 breast cancer cells,”Toxicology Letters,
vol. 192, no. 2, pp. 119–125, 2010.
[27] T. P. Stanojkovic´, A. Konic´-Ristic´, Z. D. Juranic´ et al., “Cytotoxic
and cell cycle effects induced by two herbal extracts on human
cervix carcinoma and human breast cancer cell lines.,” Journal
of medicinal food, vol. 13, no. 2, pp. 291–297, 2010.
[28] Y. Xu, Z. Jiang, G. Ji, and J. Liu, “Inhibition of bone metastasis
from breast carcinoma by rosmarinic acid,” Planta Medica, vol.
76, no. 10, pp. 956–962, 2010.
[29] S. J. Conde, R. D. A. M. Luvizotto, M. T. De Sı´bio, and C.
R. Nogueira, “Human breast tumor slices as an alternative
approach to cell lines to individualize research for each patient,”
European Journal of Cancer Prevention, vol. 21, no. 4, pp. 333–
335, 2012.
[30] I. A. M. de Graaf, P. Olinga, M. H. de Jager et al., “Preparation
and incubation of precision-cut liver and intestinal slices for
application in drug metabolism and toxicity studies,” Nature
Protocols, vol. 5, no. 9, pp. 1540–1551, 2010.
[31] M. Possidente, S. Dragoni, G. Franco et al., “Rat intestinal
precision-cut slices as an in vitro model to study xenobiotic
interaction with transporters,” European Journal of Pharmaceu-
tics and Biopharmaceutics, vol. 79, no. 2, pp. 343–348, 2011.
[32] P. Olinga and D. Schuppan, “Precision-cut liver slices: a tool to
model the liver ex vivo,” Journal of Hepatology, vol. 58, no. 6, pp.
1252–1253, 2013.
[33] R. DeKanter, A. Tuin, E. van deKerkhof et al., “A new technique
for preparing precision-cut slices from small intestine and colon
for drug biotransformation studies,” Journal of Pharmacological
and Toxicological Methods, vol. 51, no. 1, pp. 65–72, 2005.
[34] H.-U. Kasper, V. Dries, U. Drebber, M. A. Kern, H. P. Dienes,
and P. Schirmacher, “Precision cut tissue slices of the liver as
morphological tool for investigation of apoptosis,” In Vivo, vol.
19, no. 2, pp. 423–432, 2005.
[35] P. Carranza-Rosales, M. G. Santiago-Mauricio, N. E. Guzma´n-
Delgado et al., “Precision-cut hamster liver slices as an ex vivo
model to study amoebic liver abscess,” Experimental Parasitol-
ogy, vol. 126, no. 2, pp. 117–125, 2010.
[36] P. Carranza-Rosales, M. G. Santiago-Mauricio, N. E. Guzma´n-
Delgado et al., “Induction of virulence factors, apoptosis, and
cytokines in precision-cut hamster liver slices infected with
Entamoeba histolytica,” Experimental Parasitology, vol. 132, no.
4, pp. 424–433, 2012.
[37] T. O. Kirby, A. Rivera, D. Rein et al., “A novel ex vivo model
system for evaluation of conditionally replicative adenoviruses
therapeutic efficacy and toxicity,” Clinical Cancer Research, vol.
10, no. 24, pp. 8697–8703, 2004.
[38] M. A. Stoff-Khalili, A. A. Rivera, L. P. Le et al., “Employment
of liver tissue slice analysis to assay hepatotoxicity linked to
replicative and nonreplicative adenoviral agents,” Cancer Gene
Therapy, vol. 13, no. 6, pp. 606–618, 2006.
[39] M. G. Rots, M. G. L. Elferink, W. M. Gommans et al., “An ex
vivo human model system to evaluate specificity of replicating
and non-replicating gene therapy agents,” The Journal of Gene
Medicine, vol. 8, no. 1, pp. 35–41, 2006.
[40] M. Zimmermann, S. Armeanu, I. Smirnow et al., “Human
presicion-cut liver tumor slices as a tumor patient-individual
predictives test system for oncolytic measles vaccine viruses,”
International Journal of Oncology, vol. 34, no. 5, pp. 1247–1256,
2009.
[41] M. A. van Geer, K. F. D. Kuhlmann, C. T. Bakker, F. J. W. ten
Kate, R. P. J. O. Elferink, and P. J. Bosma, “Ex-vivo evaluation of
gene therapy vectors in human pancreatic (cancer) tissue slices,”
World Journal of Gastroenterology, vol. 15, no. 11, pp. 1359–1366,
2009.
[42] M. A. Kern, A. M. Haugg, E. Eiteneuer et al., “Ex vivo analysis
of antineoplastic agents in precision-cut tissue slices of human
origin: effects of cyclooxygenase-2 inhibition in hepatocellular
carcinoma,”Liver International, vol. 26, no. 5, pp. 604–612, 2006.
[43] P. Mestres, A. Morguet, W. Schmidt, A. Kob, and E. Thedinga,
“A new method to assess drug sensitivity on breast tumor acute
slices preparation,” Annals of the New York Academy of Sciences,
vol. 1091, pp. 460–469, 2006.
[44] H. van der Kuip, T. E. Mu¨rdter, M. Sonnenberg et al., “Short
term culture of breast cancer tissues to study the activity of the
anticancer drug taxol in an intact tumor environment,” BMC
Cancer, vol. 6, article 86, 2006.
[45] N. Parajuli and W. Doppler, “Precision-cut slice cultures of
tumors from MMTV-neu mice for the study of the ex vivo
response to cytokines and cytotoxic drugs,” In Vitro Cellular
& Developmental Biology—Animal, vol. 45, no. 8, pp. 442–450,
2009.
12 BioMed Research International
[46] R. Pazdur, A. P. Kudelka, J. J. Kavanagh, P. R. Cohen, and
M. N. Raber, “The taxoids: paclitaxel (Taxol) and docetaxel
(Taxotere),” Cancer Treatment Reviews, vol. 19, no. 4, pp. 351–
386, 1993.
[47] D. Lister-Sharp, M. S. McDonagh, K. S. Khan, and J. Kleijnen,
“A rapid and systematic review of the effectiveness and cost-
effectiveness of the taxanes used in the treatment of advanced
breast and ovarian cancer,” Health Technology Assessment, vol.
4, no. 17, pp. 1–113, 2000.
[48] K. D. Miller and G. W. Sledge Jr., “Taxanes in the treatment of
breast cancer: a prodigy comes of age,”Cancer Investigation, vol.
17, no. 2, pp. 121–136, 1999.
[49] C. C. Neto, A. J. Vaisberg, B.-N. Zhou, D. G. I. Kingston, and
G. B. Hammond, “Cytotoxic triterpene acids from the peruvian
medicinal plant Polylepis racemosa,” Planta Medica, vol. 66, no.
5, pp. 483–484, 2000.
[50] E. Evdokimova, H. Taper, and P. B. Calderon, “Effects of
bacterial endotoxin (lipopolysaccharides) on survival and
metabolism of cultured precision-cut rat liver slices,” Toxicology
in Vitro, vol. 16, no. 1, pp. 47–54, 2002.
[51] S. Gurunathan, J. W. Han, V. Eppakayala, M. Jeyaraj, and J.-H.
Kim, “Cytotoxicity of biologically synthesized silver nanopar-
ticles in MDA-MB-231 human breast cancer cells,” BioMed
Research International, vol. 2013, Article ID 535796, 10 pages,
2013.
[52] S. M. Veronese, M. Gambacorta, O. Gottardi, F. Scanzi, M.
Ferrari, and P. Lampertico, “Proliferation index as a prognostic
marker in breast cancer,” Cancer, vol. 71, no. 12, pp. 3926–3931,
1993.
[53] J. A. Hickman, R. Graeser, R. de Hoogt et al., “Three-
dimensional models of cancer for pharmacology and cancer
cell biology: capturing tumor complexity in vitro/ex vivo,”
Biotechnology Journal, vol. 9, no. 9, pp. 1115–1128, 2014.
[54] J.-S. Diallo, D. Roy, H. Abdelbary, N. de Silva, and J. C. Bell, “Ex
vivo infection of live tissue with oncolytic viruses,” Journal of
Visualized Experiments, no. 52, Article ID e2854, 2011.
[55] D. L. Holliday, M. A. Moss, S. Pollock et al., “The practicalities
of using tissue slices as preclinical organotypic breast cancer
models,” Journal of Clinical Pathology, vol. 66, no. 3, pp. 253–
255, 2013.
[56] F. Pirnia, S. Frese, B. Gloor et al., “Ex vivo assessment of
chemotherapy-induced apoptosis and associated molecular
changes in patient tumor samples,”Anticancer Research, vol. 26,
no. 3, pp. 1765–1772, 2006.
[57] L. Horev-Azaria, G. Baldi, D. Beno et al., “Predictive Toxicology
of cobalt ferrite nanoparticles: comparative in-vitro study of
different cellular models using methods of knowledge discovery
from data,” Particle and Fibre Toxicology, vol. 10, no. 1, article 32,
2013.
[58] C. N. Ramirez, C. Antczak, and H. Djaballah, “Cell viability
assessment: toward content-rich platforms,” Expert Opinion on
Drug Discovery, vol. 5, no. 3, pp. 223–233, 2010.
[59] S. N. Rampersad, “Multiple applications of alamar blue as
an indicator of metabolic function and cellular health in cell
viability bioassays,” Sensors, vol. 12, no. 9, pp. 12347–12360, 2012.
[60] R. Yerushalmi, R. Woods, P. M. Ravdin, M. M. Hayes, and K.
A. Gelmon, “Ki67 in breast cancer: prognostic and predictive
potential,”The Lancet Oncology, vol. 11, no. 2, pp. 174–183, 2010.
[61] C. Milani, J. Welsh, M. L. H. Katayama et al., “Human breast
tumor slices: a model for identification of vitamin D regulated
genes in the tumor microenvironment,” The Journal of Steroid
Biochemistry andMolecular Biology, vol. 121, no. 1-2, pp. 151–155,
2010.
[62] M. Sonnenberg, H. van der Kuip, S. Haubeiß et al., “Highly
variable response to cytotoxic chemotherapy in carcinoma-
associated fibroblasts (CAFs) from lung and breast,” BMC
Cancer, vol. 8, article 364, 2008.
[63] M. Kampa, V.-I. Alexaki, G. Notas et al., “Antiproliferative and
apoptotic effects of selective phenolic acids on T47D human
breast cancer cells: potential mechanisms of action,” Breast
Cancer Research, vol. 6, no. 2, pp. R63–R74, 2004.
[64] A. Bishayee, S. Ahmed, N. Brankov, and M. Perloff, “Triter-
penoids as potential agents for the chemoprevention and
therapy of breast cancer,” Frontiers in Bioscience, vol. 16, no. 3,
pp. 980–996, 2011.
[65] P. J. Morin, “Drug resistance and the microenvironment: nature
and nurture,”Drug Resistance Updates, vol. 6, no. 4, pp. 169–172,
2003.
[66] H.-T. Chang, I.-L. Chen, C.-T. Chou et al., “Effect of caffeic
acid onCa2+ homeostasis and apoptosis in SCM1 human gastric
cancer cells,”Archives of Toxicology, vol. 87, no. 12, pp. 2141–2150,
2013.
[67] T. Luo, J. Wang, Y. Yin et al., “(-)-Epigallocatechin gallate sensi-
tizes breast cancer cells to paclitaxel in amurinemodel of breast
carcinoma,” Breast Cancer Research, vol. 12, no. 1, article R8,
2010.
[68] Y. Li, D. Xing, Q. Chen, and W. R. Chen, “Enhancement of
chemotherapeutic agent-induced apoptosis by inhibition ofNF-
kappaB using ursolic acid,” International Journal of Cancer, vol.
127, no. 2, pp. 462–473, 2010.
[69] G.-Q. Chen, Z.-W. Yao, W.-P. Zheng, L. Chen, H. Duan, and
Y. Shen, “Combined antitumor effect of ursolic acid and 5-
fluorouracil on human esophageal carcinoma cell Eca-109 in
vitro,” Chinese Journal of Cancer Research, vol. 22, no. 1, pp. 62–
67, 2010.
[70] M. Gonza´lez-Vallinas, S. Molina, G. Vicente et al., “Antitumor
effect of 5-fluorouracil is enhanced by rosemary extract in both
drug sensitive and resistant colon cancer cells,” Pharmacological
Research, vol. 72, pp. 61–68, 2013.
[71] C.-L. Lin, R.-F. Chen, J. Y.-F. Chen et al., “Protective effect of
caffeic acid on paclitaxel induced anti-proliferation and apop-
tosis of lung cancer cells involves NF-𝜅b pathway,” International
Journal of Molecular Sciences, vol. 13, no. 5, pp. 6236–6245, 2012.
[72] L. H. Lash and R. K. Zalups, “Mercuric chloride-induced
cytotoxicity and compensatory hypertrophy in rat kidney prox-
imal tubular cells,” Journal of Pharmacology and Experimental
Therapeutics, vol. 261, no. 2, pp. 819–829, 1992.
[73] D. M. Kendig and J. B. Tarloff, “Inactivation of lactate dehydro-
genase by several chemicals: implications for in vitro toxicology
studies,” Toxicology in Vitro, vol. 21, no. 1, pp. 125–132, 2007.
[74] M. C. Hohnholt, E. M. Blumrich, and R. Dringen, “Multiassay
analysis of the toxic potential of hydrogen peroxide on cultured
neurons,” Journal of Neuroscience Research, 2014.
[75] K. Tulpule, M. C. Hohnholt, J. Hirrlinger, and R. Dringen,
“Primary cultures of astrocytes and neurons as model systems
to study the metabolism and metabolite export from brain
cells,” in Brain Energy Metabolism, J. Hirrlinger and W. S.
Waagepetersen, Eds., vol. 90, pp. 45–72, Springer, New York,
NY, USA, 2014.
[76] M. da Silva Morrone, A. M. de Assis, R. F. da Rocha et al.,
“Passifloramanicata (Juss.) aqueous leaf extract protects against
reactive oxygen species and protein glycation in vitro and ex
BioMed Research International 13
vivo models,” Food and Chemical Toxicology, vol. 60, pp. 45–51,
2013.
[77] Y. Liu, L. Cao, J. Du et al., “Protective effects of Lycium bar-
barum polysaccharides against carbon tetrachloride-induced
hepatotoxicity in precision-cut liver slices in vitro and in vivo in
common carp (Cyprinus carpio L.),” Comparative Biochemistry
and Physiology Part C: Toxicology and Pharmacology, vol. 169,
pp. 65–72, 2015.
[78] M. Gerlinger, A. J. Rowan, S. Horswell et al., “Intratumor
heterogeneity and branched evolution revealed by multiregion
sequencing,”TheNew England Journal of Medicine, vol. 366, no.
10, pp. 883–892, 2012.
[79] M. Eichelbaum, N. Spannbrucker, and H. J. Dengler, “Proceed-
ings: N-oxidation of sparteine in man and its interindividual
differences,” Naunyn-Schmiedeberg’s Archives of Pharmacology,
vol. 287, supplement R94, 1975.
[80] W.-Q. Ge, J.-X. Pu, and S.-Y. Zheng, “Clinical application of
the adenosine triphosphate-based response assay in intravesical
chemotherapy for superficial bladder cancer,” Asian Pacific
Journal of Cancer Prevention, vol. 13, no. 2, pp. 689–692, 2012.
[81] C.Marquette and L. Nabell, “Chemotherapy-resistant metastat-
ic breast cancer,”Current Treatment Options in Oncology, vol. 13,
no. 2, pp. 263–275, 2012.
